AbbVie Inc (NYSE:ABBV) – Investment analysts at William Blair reduced their Q3 2018 EPS estimates for shares of AbbVie in a note issued to investors on Monday, October 15th. William Blair analyst Y. Xu now expects that the company will post earnings of $1.93 per share for the quarter, down from their previous estimate of $1.94. William Blair also issued estimates for AbbVie’s Q4 2018 earnings at $2.00 EPS, FY2018 earnings at $7.81 EPS and FY2019 earnings at $8.10 EPS.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 27th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.02. The business had revenue of $8.28 billion for the quarter, compared to analyst estimates of $8.22 billion. AbbVie had a return on equity of 362.05% and a net margin of 20.84%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. During the same period last year, the company posted $1.42 EPS.
NYSE:ABBV opened at $89.90 on Wednesday. The company has a debt-to-equity ratio of -9.06, a quick ratio of 0.71 and a current ratio of 0.80. AbbVie has a 12 month low of $85.24 and a 12 month high of $125.86. The stock has a market capitalization of $143.22 billion, a price-to-earnings ratio of 16.17, a P/E/G ratio of 0.91 and a beta of 1.54.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Signature Estate & Investment Advisors LLC acquired a new position in AbbVie in the third quarter worth about $112,000. Mainstay Capital Management LLC ADV grew its stake in AbbVie by 6,123.5% in the second quarter. Mainstay Capital Management LLC ADV now owns 12,447 shares of the company’s stock worth $143,000 after purchasing an additional 12,247 shares in the last quarter. Fairfield Bush & CO. acquired a new position in AbbVie in the first quarter worth about $146,000. First Mercantile Trust Co. acquired a new position in AbbVie in the second quarter worth about $150,000. Finally, Centaurus Financial Inc. acquired a new position in AbbVie in the first quarter worth about $153,000. 69.35% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Michael Severino sold 50,000 shares of AbbVie stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $97.52, for a total transaction of $4,876,000.00. Following the sale, the executive vice president now directly owns 111,481 shares of the company’s stock, valued at $10,871,627.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.07% of the stock is currently owned by insiders.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 15th. Stockholders of record on Monday, October 15th will be given a dividend of $0.96 per share. This represents a $3.84 dividend on an annualized basis and a dividend yield of 4.27%. The ex-dividend date of this dividend is Friday, October 12th. AbbVie’s payout ratio is 68.57%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
See Also: Risk Tolerance
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.